Abstract 1951P
Background
Angiosarcoma is a rare and aggressive cancer of the endothelial cells. It has been shown that β-adrenergic signaling through the β-adrenoceptors (ADRB) 1 and 2, that are overexpressed in angiosarcoma, promotes tumor growth. Propranolol, a non-selective β-blocker, was able to initiate apoptosis in angiosarcoma cell lines and its anti-tumor activity has been demonstrated in several case reports. The aim of this window-of opportunity trial was to prospectively evaluate the anti-tumor activity of propranolol in patients with angiosarcoma.
Methods
Patients with angiosarcoma with a waiting time of 3 to 6 weeks until start of standard treatment were eligible. Propranolol was dosed 80 mg to 240 mg/day according to a dose titration schedule. The primary endpoint was clinical response rate. Clinical response was defined as either complete response (CR), partial response (PR) (according to RECIST 1.1) or stable disease (SD) with improvement of erythema, edema and thickness. Exploratory objectives included histologic response, PET response and assessment of potential biomarkers for response in tumor tissue by IHC (e.g., ADBR 1/2, PD-L1).
Results
To date, 13 patients with a median age of 67 years (range 52-86) are enrolled and have initiated treatment. The median duration of treatment was 28 days (range 21-42 days). The median dose was 160 mg/day. Three patients showed exceptional good tolerance (blood pressure/heart rate) and could be escalated to the highest dose (240 mg/day). Two patients showed clinical response. The most common adverse event was grade 1/2 bradycardia (85%). There were no grade ≥3 adverse events. Preliminary IHC results showed ADBR2 overexpression in the majority of the tumors (12 out of 17 tumor samples, both in responders and non-responders). None of the tumors showed ADBR1 overexpression.
Conclusions
This window-of-opportunity trial did not demonstrate clinical efficacy of propranolol monotherapy in patients with angiosarcoma. Two out of 13 patients did however show clinical benefit. ADBR1 or 2 expression did not correlate with response. Translational research to better comprehend the anti-tumor activity of propranolol for adequate selection of patients in future studies is ongoing (e.g., immune system-based biomarkers).
Clinical trial identification
NCT04518124.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Anticancer Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15